Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East
Mont-Saint-Guibert, Belgium – February 18, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced continued progress in strengthening its presence in the Middle East through the signature of a Memorandum of Understanding (MoU) with Sheikh Shakhbout Medical City (SSMC), a flagship hospital in the United Arab Emirates for serious and complex care and a subsidiary of PureHealth, the largest healthcare group in the Middle East. This MoU reflects Nyxoah’s strategic focus on working with leading regional medical centers to expand access to its Genio® hypoglossal nerve stimulation (HGNS) therapy, while supporting the highest standards of clinical care, education, and scientific collaboration.
As part of this MoU, Nyxoah and SSMC are engaged in initiatives aimed at positioning SSMC as a leading regional center for Genio therapy. These efforts are intended to support the development of a high-volume implant program with a strong focus on patient-centered care.
In parallel, the collaboration includes plans to establish SSMC as a regional training hub for Genio therapy in the Middle East to support the education of surgeons, sleep physicians, and referring healthcare professionals from across the region.
Nyxoah and SSMC are also engaged in discussions to explore clinical research and collaboration in the field of sleep apnea, chronic and metabolic disease management.
Olivier Taelman, Chief Executive Officer of Nyxoah, commented: “Given the high prevalence of Obstructive Sleep Apnea in the Middle East, this initiative supports our vision to offer new treatment options to patients in the region and further explore the impact of advanced OSA management on chronic and metabolic diseases such as type 2 diabetes. Our active engagement with Sheikh Shakhbout Medical City reflects our strategy of partnering with leading institutions to build sustainable clinical programs, support physician education, and contribute to the advancement of care for patients living with obstructive sleep apnea.”
Dr. Marwan Al Kaabi, Chief Executive Officer of Sheikh Shakhbout Medical City, added: “At Sheikh Shakhbout Medical City, we are committed to advancing specialized, high-quality care through clinical excellence, education, and research. Our collaboration with Nyxoah supports our efforts to further develop expertise in innovative sleep apnea therapies and to serve as a regional reference center for training and scientific exchange.”
